About Clyde Biosciences
Clyde Biosciences is a company based in Holytown (United Kingdom) founded in 2012 by Godfrey Smith and Francis Burton. Clyde Biosciences has raised $3.5 million across 2 funding rounds from investors including University of Glasgow, Scottish Enterprise and European Union. The company has 6 employees as of July 31, 2022. Clyde Biosciences offers products and services including CellOPTIQ Platform, CiPA Assay, and Heart Failure Assay. Clyde Biosciences operates in a competitive market with competitors including Anabios, Metrion Biosciences, Quiver Bioscience, Zen-Bio and Rules-Based Medicine, among others.
- Headquarter Holytown, United Kingdom
- Employees 6 as on 31 Jul, 2022
- Founders Godfrey Smith, Francis Burton
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Clyde Biosciences Limited
- Date of Incorporation 07 Mar, 2012
- Jurisdiction MOTHERWELL, LANARKSHIRE, SCOTLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.5 M (USD)
in 2 rounds
-
Latest Funding Round
$300.9 K (USD), Grant
Sep 01, 2015
-
Investors
University of Glasgow
& 3 more
-
Employee Count
6
as on Jul 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Clyde Biosciences
Clyde Biosciences offers a comprehensive portfolio of products and services, including CellOPTIQ Platform, CiPA Assay, and Heart Failure Assay.
Measures voltage, calcium, and contractility in cardiomyocytes for drug safety.
Predicts pro-arrhythmic risks using human stem cell-derived cardiomyocytes.
Evaluates drug effects on cardiac function for heart failure studies.
Funding Insights of Clyde Biosciences
Clyde Biosciences has successfully raised a total of $3.5M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $300.9 thousand completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Clyde Biosciences
Clyde Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include University of Glasgow, Scottish Enterprise and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Business development and leadership training programs are offered to companies.
|
Locked | Locked | Locked |
Investor details for Clyde Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Clyde Biosciences
Investment portfolio details for Clyde Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Clyde Biosciences
Detailed financials for Clyde Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Clyde Biosciences Comparisons
Peer comparison for Clyde Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Clyde Biosciences
Clyde Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Anabios, Metrion Biosciences, Quiver Bioscience, Zen-Bio and Rules-Based Medicine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ex-vivo human tissue studies are performed for preclinical drug discovery.
|
|
| Locked | Locked | Locked |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| Locked | Locked | Locked |
Developer of transformational medicines for neurological disorders
|
|
| Locked | Locked | Locked |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| Locked | Locked | Locked |
Multiplexed immunoassays for protein biomarkers are developed via proprietary platform.
|
Detailed competitors of Clyde Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Clyde Biosciences
Complete news archive for Clyde Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Clyde Biosciences
Clyde Biosciences was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Clyde Biosciences is headquartered in Holytown, United Kingdom. It is registered at Holytown, North Lanarkshire, United Kingdom.
Clyde Biosciences is a funded company, having raised a total of $3.5M across 2 funding rounds to date.
As of Jul 31, 2022, the latest employee count at Clyde Biosciences is 6.
Clyde Biosciences is a boutique Contract Research Organisation for cardiac safety testing. Clydes CellOPTIQ platform delivers high-resolution functional output from a range of cardiac cell types including iPS-derived heart cells. High bandwidth membrane voltage signals from CellOPTIQ provides insights into electrophysiological effects of drugs. Rapid data capture and analysis is made possible by their bespoke software which allows accelerated assay throughput in a 96 well format. Their services include Calcium, Voltage, Contractility, In Silico Modelling, CiPA Studies, Bespoke RD.
Clyde Biosciences's top competitors include Metrion Biosciences, Quiver Bioscience and Anabios.
Clyde Biosciences offers CellOPTIQ Platform, CiPA Assay, and Heart Failure Assay.
Clyde Biosciences has 4 investors. Key investors include University of Glasgow, Scottish Enterprise, European Union, and Epidarex Capital.
The valuation of Clyde Biosciences is $5.2M as of Mar 2015.